Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data

Frey S, Linder R, Juckel G, Stargardt T

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1007/s10198-013-0460-9

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Antipsychotic Agents /economics /therapeutic use; Cost-Benefit Analysis; Delayed-Action Preparations; Female; Flupenthixol /analogs & derivatives /economics /therapeutic use; Hospitalization /economics; Humans; Male; Markov Chains; Middle Aged; Models, Econometric; Risperidone /economics /therapeutic use; Schizophrenia /drug therapy

AccessionNumber
22014020015

Date bibliographic record published
19/11/2014